ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
63,324.26
-2.36%
S&P 500
5,631.22
0.28%
Dow Jones
40,211.72
0.53%
US Dollar vs Yen
158.361
0.14%
Brent Oil
83.60
-0.88%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Seelos Therapeutics Inc (SEEL)

  7. Seelos Therapeutics Inc (SEEL) ニュース

SEEL

Seelos Therapeutics (SEEL)

Seelos Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:SEEL
日付受信時刻ニュースソース見出しコード企業名
2019/12/0422 : 00GlobeNewswire Inc.Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) NASDAQ:SEELSeelos Therapeutics Inc
2019/12/0320 : 01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SEELSeelos Therapeutics Inc
2019/12/0306 : 52Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SEELSeelos Therapeutics Inc
2019/11/2801 : 00GlobeNewswire Inc.Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)NASDAQ:SEELSeelos Therapeutics Inc
2019/11/2206 : 32Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:SEELSeelos Therapeutics Inc
2019/11/2023 : 00GlobeNewswire Inc.Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)NASDAQ:SEELSeelos Therapeutics Inc
2019/11/1822 : 00GlobeNewswire Inc.Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)NASDAQ:SEELSeelos Therapeutics Inc
2019/11/0821 : 00GlobeNewswire Inc.Seelos Therapeutics Reports Q3 2019 Pipeline UpdateNASDAQ:SEELSeelos Therapeutics Inc
2019/11/0807 : 02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SEELSeelos Therapeutics Inc
2019/11/0806 : 21Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SEELSeelos Therapeutics Inc
2019/11/0123 : 00GlobeNewswire Inc.Seelos Therapeutics to Participate in Upcoming Investor Conferences in DecemberNASDAQ:SEELSeelos Therapeutics Inc
2019/10/2122 : 00GlobeNewswire Inc.Seelos Therapeutics Announces Amendment of SLS-002 AgreementNASDAQ:SEELSeelos Therapeutics Inc
2019/10/2121 : 58Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SEELSeelos Therapeutics Inc
2019/10/1822 : 00GlobeNewswire Inc.Seelos Therapeutics to Participate in Upcoming Investor Conference in NovemberNASDAQ:SEELSeelos Therapeutics Inc
2019/10/1522 : 00GlobeNewswire Inc.Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory ConsultantNASDAQ:SEELSeelos Therapeutics Inc
2019/09/0422 : 00GlobeNewswire Inc.Seelos Therapeutics to Participate in Upcoming Investor Conference in SeptemberNASDAQ:SEELSeelos Therapeutics Inc
2019/08/3105 : 35Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:SEELSeelos Therapeutics Inc
2019/08/2805 : 32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SEELSeelos Therapeutics Inc
2019/08/2619 : 01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:SEELSeelos Therapeutics Inc
2019/08/2322 : 00GlobeNewswire Inc.Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct OfferingNASDAQ:SEELSeelos Therapeutics Inc
2019/08/2319 : 06Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SEELSeelos Therapeutics Inc
2019/08/2222 : 00GlobeNewswire Inc.Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Sy...NASDAQ:SEELSeelos Therapeutics Inc
2019/08/1605 : 32Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SEELSeelos Therapeutics Inc
2019/08/1507 : 00GlobeNewswire Inc.Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SEELSeelos Therapeutics Inc
2019/08/1505 : 39Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SEELSeelos Therapeutics Inc
2019/08/0622 : 00GlobeNewswire Inc.Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12thNASDAQ:SEELSeelos Therapeutics Inc
2019/08/0122 : 03Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SEELSeelos Therapeutics Inc
2019/08/0122 : 00GlobeNewswire Inc.Seelos Therapeutics Reports Q2 2019 Pipeline UpdateNASDAQ:SEELSeelos Therapeutics Inc
2019/07/1722 : 08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SEELSeelos Therapeutics Inc
2019/07/1722 : 00GlobeNewswire Inc.Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005NASDAQ:SEELSeelos Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SEEL

最近閲覧した銘柄

NASDAQ
MSFT
Microsoft
COIN
BTCUSD
Bitcoin
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
NYSE
DIS
Walt Disney
NYSE
AXP
American Express
NASDAQ
TSLA
Tesla
NASDAQ
AMZN
Amazon.com
SPI
SP500
S&P 500
USOTC
ADDYY
Adidas (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
NKE
Nike
AMEX
XLE
Energy Select Sector SPDR
FX
USDEUR
US Dollar vs Euro
CCOM
US100
US Tech 100
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有